Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Nanoform Finland Plc | Company Release | April 02, 2026 at 09:30:00 EEST
Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s General Counsel and Chief Development Officer Peter Hänninen’s purchase of Nanoform Finland Plc shares:
Nanoform Finland Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Peter Hänninen
Position: Other senior manager
Issuer: Nanoform Finland Oyj
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 150161/5/4
____________________________________________
Transaction date: 2026-04-01
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000330972
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 10111 Unit price: 0.445 EUR
(2): Volume: 12088 Unit price: 0.4425 EUR
(3): Volume: 11196 Unit price: 0.4425 EUR
(4): Volume: 9481 Unit price: 0.443 EUR
(5): Volume: 3022 Unit price: 0.432 EUR
(6): Volume: 2458 Unit price: 0.431 EUR
(7): Volume: 888 Unit price: 0.432 EUR
(8): Volume: 756 Unit price: 0.431 EUR
Aggregated transactions (8):
Volume: 50000 Volume weighted average price: 0.44154 EUR
For further information, please contact:
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.